FDA examines conflict-of-interest policies (The Olympian)
WASHINGTON - Stung by recent criticism that some of its advisory board members have undisclosed financial ties to drug makers, the U.S. Food and Drug Administration announced Monday its plans to strengthen and clarify rules about who can sit on the consulting panels.

Cepheid's Xpert GBS(TM) Test For Group B Streptococcus Run On The GeneXpert(R) System Receives 510(k) Clearance From FDA (Medical News Today)
Cepheid (Nasdaq:CPHD), a broad-based molecular diagnostics company, today announced the510(k) clearance of its first clinical molecular diagnostic product for theUnites States market. Cepheid received 510(k) clearance from the U.S. Food& Drug Administration (FDA) to market its Xpert GBS(TM) test for Group BStreptococcus (GBS) on its GeneXpert(R) platform. [click link for full article]

VIVUS Reports Second Quarter 2006 Financial Results and Product Development Highlights (Boursorama)
MOUNTAIN VIEW, Calif.,